GCS (German Cannabis Standard) operates a vertically integrated ecosystem spanning research, cultivation, digital telemedicine and pharmacy distribution for medical cannabis. Its technology suite includes Blütezeit Health (B2C/telemedicine), Cannaflow (B2B infrastructure & ERP) and Cannabiosan (an apothecary purchasing cooperative). The company is constructing a GMP‑certified production facility in Solar Valley Bitterfeld‑Wolfen of about 21,000 square metres, intended as one of Germany's three largest medical‑cannabis production sites. Construction has already begun and the facility will be certified by the German Federal Institute for Drugs and Medical Devices (BfArM). A German family office provided a significant portion of the recent financing and the production space. The company reports the financing is based on a €60 million valuation. GCS says recent regulatory changes under the Medizinal‑Cannabis‑Gesetz (April 2024) have opened the German market and improved planning certainty for its integrated business model.

Total raised

$12M

Funding rounds

1

Latest round

Equity

Latest activity

Sep 2025